<DOC>
	<DOCNO>NCT02511405</DOCNO>
	<brief_summary>The purpose pivotal , phase 3 , randomize , multicenter study compare VB-111 plus bevacizumab bevacizumab adult patient recurrent Glioblastoma .</brief_summary>
	<brief_title>A Phase 3 , Pivotal Trial VB-111 Plus Bevacizumab vs. Bevacizumab Patients With Recurrent Glioblastoma ( GLOBE )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . First second progression Glioblastoma ; 2 . Measurable disease RANO criterion progression ; 3 . Patients ≥18 year age ; 4 . Patient may operate recurrence . If operate : residual measurable disease surgery require ; 5 . Surgery complete least 28 day randomization ; 6 . An interval least 12 week prior radiotherapy least 23 day prior chemotherapy , 42 day nitrosoureas enrollment study ; 7 . Adequate performance , i.e . `` Karnofsky Performance Score '' least 70 % ; 8 . Adequate renal , liver , bone marrow function accord follow criterion : Absolute neutrophil count ≥1500 cells/ml , Platelets ≥ 100,000 cells/ml , Total bilirubin within upper limit normal ( ULN ) , Aspartate aminotransferase ( AST ) ≤ 2.0 X ULN , Serum creatinine level ≤ ULN creatinine clearance ≥ 50 ml/min patient creatinine level normal limit ( creatinine clearance calculate CockcroftGault formula , see Appendix II ) , PT , PTT ( second ) prolong beyond &gt; 20 % upper limit normal . 1 . Prior antiangiogenic therapy include VEGF sequester agent ( i.e . bevacizumab , aflibercept , etc . ) VEGFR inhibitor ( cedirinib , pazopanib , sunitinib , sorafenib , etc . ) ; 2 . Prior stereotactic radiotherapy ; 3 . Pregnant breastfeeding patient ; 4 . Concomitant medication may interfere study result ; e.g . immunosuppressive agent corticosteroid ; 5 . Active infection ; 6 . Evidence significant CNS haemorrhage i.e . CTCAE grade 2 ; 7 . Expected surgery study period ; 8 . Patients active vascular disease , either myocardial peripheral ( i.e . acute coronary syndrome , cerebral stroke , transient ischemic attack arterial thrombosis symptomatic peripheral vascular disease within past 3 month ) ; 9 . Patients know proliferative and/or vascular retinopathy ; 10 . Patients know liver disease ( alcoholic , drug/toxin induce , genetic , autoimmune ) ; 11 . Patients know active second malignancy nonmelanoma skin cancer , nonmetastatic prostate cancer , situ cervical cancer , ductal lobular carcinoma situ breast . Patients consider currently active malignancy complete anticancer therapy disease free great 2 year prior screen ; 12 . Patients test positive one follow virus : HIV , HBV HCV within last 6 month ; 13 . Patients undergone major surgery within last 4 week enrollment ; 14 . Patients receive treatment investigational agent within 4 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>rGBM</keyword>
	<keyword>Recurrent Glioblastoma</keyword>
	<keyword>Recurrent GBM</keyword>
</DOC>